How Long Does It Take for Emgality to Work?

Emgality (galcanezumab) can start reducing migraine days within the first week of injection, with clinical trial data detecting a measurable effect as early as the day after the first dose. That said, the drug’s full preventive benefit builds over the first one to three months, and the timeline varies depending on whether you have episodic migraine, chronic migraine, or cluster headache. The speed of this onset surprised researchers when the pivotal trials were analyzed, because older preventive medications for migraine typically require weeks or months before patients notice any change at all.

What the Clinical Trials Found in the First Week

Two large randomized trials, known as EVOLVE-1 and EVOLVE-2, enrolled people with episodic migraine and tracked their headache days carefully from the very first injection. When researchers broke down the first month day by day, they found that galcanezumab separated from placebo starting at Day 1, meaning the first full day after the injection. By the end of the first week, people on galcanezumab had roughly two and a half to three times the odds of having fewer migraine days compared to those on placebo. About 54 to 59 percent of treated patients had already cut their migraine days in half by that first week, compared to 32 to 38 percent on placebo.¹

Those numbers are worth putting in context. In clinical trials, the placebo group always sees some improvement because migraine frequency naturally fluctuates. The fact that over half of galcanezumab-treated patients saw their migraine days drop by at least 50 percent within one week is genuinely fast for a preventive treatment. Most older preventives, like topiramate or beta-blockers, are generally given four to eight weeks before a patient can fairly judge whether they are working. CGRP-targeting drugs like Emgality shortened that waiting period dramatically.

Why the Loading Dose Matters for Speed

The standard dosing for migraine prevention starts with a loading dose of 240 mg (two injections of 120 mg) at the first visit, followed by 120 mg once a month. That initial double dose is not arbitrary. Pharmacokinetic modeling shows that the loading dose roughly doubles the drug concentration in the first month compared to starting at 120 mg right away. More importantly, it brings galcanezumab to near-steady-state levels immediately. Without the loading dose, it would take four to five months of monthly 120 mg injections to reach the same stable drug levels.²

This is one reason Emgality can work faster than you might expect. The loading dose front-loads the drug so it reaches therapeutic concentrations right away, rather than gradually climbing over months. The drug’s half-life is about 27 days, which matches the once-monthly injection schedule nicely. Each new dose essentially tops off what the previous dose left behind.

If your prescriber skips the loading dose or you miss your first scheduled follow-up injection, the drug will still accumulate in your body, but you may not feel the full effect as quickly. This is rare, since the loading dose is part of the standard prescribing label, but it helps explain why some patients report a slower onset than others.

What to Expect Over the First One to Three Months

While many patients notice improvement in the first week or two, the benefits tend to deepen over the next several months. A real-world systematic review of studies from Spain found that patients showed clear reductions in monthly migraine days, headache days, and disability scores by three months after starting treatment. Those improvements were generally maintained or continued to grow at six and twelve months in patients who kept responding.³

A larger real-world meta-analysis pooling data from 36 studies and nearly 3,900 patients confirmed the pattern of progressive improvement. Monthly migraine day reductions ranged from about 7 fewer days at one month to nearly 11 fewer days at twelve months. Disability scores dropped steeply as well, with one commonly used disability scale showing a reduction of roughly 43 points at three months and over 50 points from six months onward.⁴

In practical terms, this means you should not judge the drug solely on your first few weeks. Even if the first month brings noticeable relief, the second and third months are likely to bring more. Headache specialists commonly recommend giving Emgality at least three monthly doses before deciding whether it is working well enough to continue.

How Response Rates Change Over Time

Looking at responder rates helps anchor expectations more concretely than averages do. Averages can be misleading because they blend strong responders with people for whom the drug does little. In the same real-world meta-analysis, about two-thirds of patients achieved at least a 50 percent reduction in migraine or headache days at the three-to-six-month mark. Roughly a third reached a 75 percent reduction, and a small group of about 2 to 7 percent became completely migraine-free.⁴

Phase 3 trial data showed that galcanezumab could produce up to a 50 percent reduction in monthly migraine days along with improved daily functioning.⁵ These are not the same as cure rates, but for people who have lived with frequent migraines, cutting them in half is often a transformative change. The key takeaway is that while some early responders notice a big shift in the first week, many more patients cross into “good response” territory between months one and three.

The Timeline for Cluster Headache

Emgality is also approved for the prevention of episodic cluster headache, which is a distinct condition from migraine and uses a different dosing schedule (300 mg at the onset of a cluster period, then monthly). The timeline for cluster headache is somewhat different. A post-hoc analysis of a phase 3 trial found that the median time to a 50 percent reduction in cluster attacks was five days with galcanezumab, compared to fourteen days with placebo. For a 75 percent reduction, the median was eleven days versus twenty-one days. Complete cessation of attacks had a median of twenty-two days versus thirty-two days.⁶

Cluster headache patients tend to see a meaningful reduction in attacks within the first one to two weeks, roughly nine to ten days sooner than placebo on average across these measures. Because cluster periods are time-limited and the attacks are extraordinarily painful, this head start over placebo can translate to dozens of avoided attacks during a cycle. Cluster headache is notoriously difficult to treat preventively, so even a partial early response carries significant weight for patients.

Does It Still Work If Other Preventives Have Failed?

Many people who end up on Emgality have already tried and failed several other preventive medications. This raises a reasonable question: is the drug less effective or slower to work in treatment-resistant patients? The evidence is actually encouraging. A subgroup analysis from the CONQUER trial specifically looked at patients who had previously failed three or four categories of preventive medication. Even in this harder-to-treat group, galcanezumab reduced monthly migraine headache days by about 5.5 days compared to roughly 1 day for placebo. The 50 percent response rate was 41 percent on the drug versus about 13 percent on placebo.⁷

The response rate in this treatment-resistant population is lower than in the general migraine trial population, which is expected. But the fact that four out of ten patients who had failed multiple prior preventives still achieved a 50 percent or better reduction is meaningful. This also suggests the timeline may feel different for some of these patients: they may be slower to reach their best response because their migraine pattern is more entrenched. But the drug is clearly not rendered ineffective by prior treatment failures, which is important to know if you are considering it after a string of disappointing medications.

Long-Term Results and Whether the Effect Holds

A natural concern with any new medication is whether the initial benefit fades over time. An Italian retrospective study followed patients for twelve months and found that monthly migraine days dropped from about 19.5 at baseline to around 8.2 at one year. Acute medication use dropped at a similar rate, from about 18.4 days per month down to 7.4 days. The therapeutic effect was maintained over the entire twelve-month treatment period with no evidence of wearing off.⁸

This aligns with the broader real-world meta-analysis, which showed that improvements in both migraine frequency and disability scores were sustained or continued to improve from months six through twelve.⁴ Loss of response, where a drug stops working after initially helping, is a known concern with some biologic therapies. With galcanezumab, the available long-term data does not suggest this is a widespread issue, though individual experiences certainly vary. If you notice a gradual return of migraine frequency after months of good control, that is worth bringing up with your prescriber, as dose adjustments or other strategies may be discussed.

What Happens When You Stop

If you stop Emgality, the benefits do not vanish overnight. In the EVOLVE-1 trial, patients who took galcanezumab for six months and then stopped were followed for an additional four months. Their migraine-day reductions declined gradually but remained significantly better than their pre-treatment baseline at every time point through month ten. For example, patients on the 120 mg dose went from a 5.2-day reduction at month six to a 4.1-day reduction at month ten, four months after their last injection. This gradual fade-out mirrors the drug’s elimination half-life of about three to four weeks; the drug lingers in the body for several months after the final injection.⁹

This has a few practical implications. First, if you are stopping Emgality for any reason, including insurance issues or a planned pregnancy, you do not need to worry about a sudden rebound of migraines the day after your missed dose. The drug clears slowly. Second, if you are switching to a different preventive, there is a built-in overlap period where galcanezumab is still partially active, which can smooth the transition. Third, the gradual return of migraine frequency after discontinuation confirms that the drug was indeed doing the work, rather than the improvement being coincidental. Some patients and their doctors use a planned discontinuation as a diagnostic tool to verify ongoing need for the medication.

When to Reassess If It Is Not Working

Given that the drug can show effects within the first week but continues to improve through month three, a reasonable question is: how long should you wait before deciding it is not working for you? Most headache specialists and clinical guidelines recommend a minimum of three months of consistent use before making a judgment. The three-month mark is when the majority of eventual responders have crossed into clear response territory based on the real-world data.³

That said, if you have seen zero change after three monthly injections, continuing past that point in hopes of a late response is harder to justify. The clinical trial data consistently shows the bulk of responders separated from placebo within the first month, and by month three, the trajectory is fairly clear. A small number of patients may continue to see incremental improvement into months four through six, but these are typically people who showed at least some early response that continued to build, not people who had no change at all and then suddenly improved.

Keeping a headache diary during the first three months is particularly valuable for this reason. Day-to-day fluctuations in migraine frequency make it hard to perceive gradual change without written records. A headache diary also captures improvements that patients sometimes overlook in self-assessment, such as reduced attack severity or shorter duration, even if the total number of headache days has not dropped as much as hoped. Your doctor will want that data to make a well-informed decision about whether to continue, switch, or adjust treatment.